Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Volker Rethwisch"'
Autor:
Michael Lübbert, Björn H. Rüter, Rainer Claus, Claudia Schmoor, Mathias Schmid, Ulrich Germing, Andrea Kuendgen, Volker Rethwisch, Arnold Ganser, Uwe Platzbecker, Oliver Galm, Wolfram Brugger, Gerhard Heil, Björn Hackanson, Barbara Deschler, Konstanze Döhner, Anne Hagemeijer, Pierre W. Wijermans, Hartmut Döhner
Publikováno v:
Haematologica, Vol 97, Iss 3 (2012)
Background The treatment of acute myeloid leukemia of older, medically non-fit patients still poses a highly unmet clinical need, and only few large, prospective studies have been performed in this setting. Given the established activity of hypomethy
Externí odkaz:
https://doaj.org/article/f169518690794aaab52479f591519dbb
Autor:
Matthias Egger, Stephan Probst, Jörg Trojan, Alexander Reichart, Dirk M Behringer, Salah-Eddin Al-Batran, Volker Rethwisch, Michael Pohl, Gerald Illerhaus, Jan Stoehlmacher, Jörg Weniger, Daniel Pink, Wael Hozaeel, Rolf Mahlberg, Georg Martin Haag, Severin Daum, Carmen Löhr, Wolff Schmiegel, Michael Heike, G. Schuch, Timo Gaiser, Flot Aio Investigators, Thorsten Oliver Goetze, Helga Bernhard, Sebastian Belle, Nils Homann, Johannes Meiler, Hans-Georg Kopp, Nicole Prasnikar, Christian Teschendorf, Andreas Block, Michael Schenk, Volker Heinemann, Markus Moehler, Stefan Kasper, Claudia Pauligk, Kim Barbara Luley, Ralf Hofheinz, Harald Schmalenberg, Michael Kneba, Frank Kullmann, Wolf O. Bechstein, Jörg T. Hartmann, Uwe M. Martens, Martin Schuler, U. Lindig, Fuat Oduncu, Peter C. Thuss-Patience, Thomas Kraus, Gunnar Folprecht, Frank Mayer, Michael Koenigsmann, Elke Jäger, Wolfgang Fischbach, Stefan Mönig, Ludwig Fischer von Weikersthal, Martina Güntner, Karsten Schulmann
Publikováno v:
The Lancet. 393:1948-1957
Background Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bb9328f246b91519e1997e982c1bc7c
https://doi.org/10.1016/s0140-6736(18)32557-1
https://doi.org/10.1016/s0140-6736(18)32557-1
Autor:
Kim Barbara Luley, Salah-Eddin Al-Batran, Markus Moehler, Ralf Hofheinz, Jan Stoehlmacher-Williams, Elke Jäger, Carsten Bokemeyer, Volker Rethwisch, Stephan Probst, Nils Homann, Frank Kullmann, Rolf Mahlberg, Claudia Pauligk, Jörg T. Hartmann, Stephan Hollerbach, Nicole Prasnikar
Publikováno v:
European Journal of Cancer. 49:835-842
We evaluated the feasibility and tolerability of triple- versus double-drug chemotherapy in elderly patients with oesophagogastric cancer.Patients aged 65 years or older with locally advanced or metastatic oesophagogastric cancer were stratified and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::424b8719614bca9cedbfe43414c3085d
https://doi.org/10.1016/j.ejca.2012.09.025
https://doi.org/10.1016/j.ejca.2012.09.025
Autor:
Salah-Eddin, Al-Batran, Joerg Thomas, Hartmann, Stephan, Probst, Harald, Schmalenberg, Stephan, Hollerbach, Ralf, Hofheinz, Volker, Rethwisch, Gernot, Seipelt, Nils, Homann, Gerhard, Wilhelm, Gunter, Schuch, Jan, Stoehlmacher, Hans Günter, Derigs, Susanna, Hegewisch-Becker, Johannes, Grossmann, Claudia, Pauligk, Akin, Atmaca, Carsten, Bokemeyer, Alexander, Knuth, Elke, Jäger, Wolfgang, Dippold
Publikováno v:
Journal of Clinical Oncology. 26:1435-1442
Purpose This study was designed to compare fluorouracil, leucovorin, and oxaliplatin with fluorouracil, leucovorin, and cisplatin in patients with advanced gastric cancer. Patients and Methods Patients with previously untreated advanced adenocarcinom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7640fc423325b04292b71152c9750f3b
https://doi.org/10.1200/jco.2007.13.9378
https://doi.org/10.1200/jco.2007.13.9378
Autor:
Pierre W. Wijermans, Björn Rüter, Gerhard Heil, Claudia Schmoor, Björn Hackanson, Konstanze Döhner, Ulrich Germing, Michael Lübbert, Oliver Galm, Anne Hagemeijer, Uwe Platzbecker, Barbara Deschler, Rainer Claus, Hartmut Döhner, Andrea Kuendgen, Arnold Ganser, Wolfram Brugger, Volker Rethwisch, Mathias Schmid
Background The treatment of acute myeloid leukemia of older, medically non-fit patients still poses a highly unmet clinical need, and only few large, prospective studies have been performed in this setting. Given the established activity of hypomethy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4bce3cbb43051517bb121d11a5629c0
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/89208
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/89208
Autor:
Stephan Probst, Elke Jäger, N. Homann, Salah-Eddin Al-Batran, R.D. Hofheinz, G. Seipelt, Claudia Pauligk, Jan Stoehlmacher, Akin Atmaca, M. Sievert, M. Fritz, Joerg T. Hartmann, R. Mahlberg, Volker Rethwisch, Michael R. Clemens
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 19(11)
Background The combination of docetaxel (Taxotere), cisplatin, and fluorouracil improved efficacy in gastric cancer, but was associated with substantial toxicity. This study was designed to incorporate docetaxel into a tolerable biweekly (once every
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf16b35855e31f08471f50c08114d2a2
https://pubmed.ncbi.nlm.nih.gov/18669868
https://pubmed.ncbi.nlm.nih.gov/18669868
Autor:
Stephan Knipping, Ulrich Keilholz, Viktor Gruenwald, Orlando Guntinas-Lichius, Norbert Frickhofen, Maren Knoedler, Andreas Dietz, Volker Rethwisch, Jan Stoehlmacher, Thomas Gauler, Michael Schroeder, Boris R. Haxel, Georg Maschmeyer
Publikováno v:
ResearcherID
e17021 Background: This study investigates efficacy and toxicity of docetaxel added to cetuximab, cisplatin and 5-FU for patients with R/M SCCHN. We here report a planned second interim analysis to compare response rates between arms in order to deci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26637fec0e9f6504b4305775bd1459d9
https://doi.org/10.1200/jco.2013.31.15_suppl.e17021
https://doi.org/10.1200/jco.2013.31.15_suppl.e17021
Autor:
Björn Rüter, Gerhard Heil, Björn Hackanson, Hartmut Döhner, Mathias Schmid, Claudia Schmoor, Uwe Platzbecker, Volker Rethwisch, Ulrich Germing, Pierre W. Wijermans, Rainer Claus, Andrea Kuendgen, Arnold Ganser, Wolfram Brugger, Oliver Galm, Michael Lübbert, Anne Hagemeijer, Konstanze Döhner
Publikováno v:
Blood. 118:2609-2609
Abstract 2609 Background: The monosomal karyotype (MK+) has recently been identified as the single most adverse cytogenetic prognosticator of AML outcome (1, 2). We made the recurrent - and seemingly paradoxical - observation that MDS/AML patients (p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9bf3485aeab76707cd810391ca649efd
https://doi.org/10.1182/blood.v118.21.2609.2609
https://doi.org/10.1182/blood.v118.21.2609.2609
Autor:
Claudia Schmoor, Arnold Ganser, Wolfram Brugger, Björn Rüter, Gerhard Heil, Uwe Platzbecker, Pierre W. Wijermans, Michael Lübbert, Björn Hackanson, Ulrich Germing, Volker Rethwisch, Hartmut Döhner, Mathias Schmid, Rainer Claus, Konstanze Döhner, Andrea Kuendgen, Oliver Galm, Barbara Deschler
Publikováno v:
Blood. 116:2185-2185
Abstract 2185 Background: Secondary (s)AML from MDS is more frequent in older AML patients, and associated with an overall worse outcome with standard chemotherapy than de novo AML, particularly after MDS of longer duration (1). The azanucleoside hyp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85686fa88b4be83899c7402f5bf7ce33
https://doi.org/10.1182/blood.v116.21.2185.2185
https://doi.org/10.1182/blood.v116.21.2185.2185
Autor:
Nicole Prasnikar, Jan Stoehlmacher, Markus Moehler, Salah-Eddin Al-Batran, Stephan Probst, Elke Jaeger, Claudia Pauligk, Volker Rethwisch, Joerg T. Hartmann, Nils Homann
Publikováno v:
Journal of Clinical Oncology. 28:4013-4013
4013 Background: Elderly patients (pts) with esophagogastric cancer often do not receive effective 3-drug combination therapies due to tolerability concerns. This study evaluates a 2- versus a 3-dr...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef47cbcc8c6a7f0c1cb9ad91c373b7c6
https://doi.org/10.1200/jco.2010.28.15_suppl.4013
https://doi.org/10.1200/jco.2010.28.15_suppl.4013